3/27/2025
Aachen, Germany, 27 March 2025 – Grünenthal, a global leader in pain management and research, has published its 2024 financial results, marking a year of impressive resilience, strategic growth and operational excellence.
A mix of strong entrepreneurial spirit, close collaboration, and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.
3/27/2025
Aachen, Germany, 27 March 2025 – Grünenthal, a global leader in pain management and research, has published its 2024 financial results, marking a year of impressive resilience, strategic growth and operational excellence.
2/24/2025
Aachen, Germany & Toronto, Canada, 24 February 2025 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain.
Florian Dieckmann
Head Global Corporate Affairs & Communication
Grünenthal GmbH
52099 Aachen
Phone +49 241 569 2555